Outlook Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended June 30, 2023; filed August 14, 2023. The company is a pre-commercial biopharmaceutical developer focused on ONS-5010 (bevacizumab-vikg), an investigational ophthalmic treatment for wet age-related macular degeneration (wet AMD). It reported no product sales revenue.
Financial results and position
| Metric | Three months ended June 30, 2023 | Nine months ended June 30, 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $11.1 million | $21.5 million | $11.2 million and $33.3 million, respectively |
| General and administrative expense | $7.0 million | $19.2 million | $5.8 million and $15.7 million, respectively |
| Operating loss | $18.1 million | $40.7 million | $17.0 million and $49.1 million, respectively |
| Net loss | $20.7 million | $46.0 million | $17.5 million and $51.7 million, respectively |
| Basic and diluted loss per share | $0.08 | $0.19 | $0.08 and $0.25, respectively |
| Operating cash flow | Not presented for the quarter | $(30.2) million | $(46.4) million for nine months |
- At June 30, cash and cash equivalents were $33.7 million; current assets were $43.0 million and current liabilities $49.9 million. Total assets were $44.4 million.
- Net cash provided by financing activities was $46.5 million for the nine months, including equity and debt proceeds; cash increased by $16.3 million to $33.7 million.
- The December 2022 convertible promissory note was carried at fair value of $34.7 million and classified as current debt. The company disclosed $35.9 million of principal, accrued interest and exit fees due at June 30. The note bears 9.5% interest and matures January 1, 2024.
- Stockholders’ equity moved from $8.7 million at September 30, 2022 to a deficit of $5.5 million at June 30, 2023. Common shares outstanding rose from 227.3 million to 258.7 million during that period.
Margins are not meaningful because the company had no product revenue.
Changes versus the prior-year periods
- Third-quarter net loss increased by $3.1 million year over year, mainly reflecting a $2.5 million larger loss from the fair-value change in promissory notes and higher G&A, partly offset by lower interest expense.
- Nine-month net loss improved by $5.7 million. R&D expense fell $11.8 million, primarily because of a $6.2 million refund of waived FDA BLA submission fees, prior-year BLA filing fees, lower stock compensation, and lower ONS-5010 development expense. G&A rose $3.4 million, principally due to pre-launch professional fees and added personnel.
- Nine-month operating cash use declined to $30.2 million from $46.4 million. Financing cash inflow also declined, to $46.5 million from $58.0 million.
Outlook, risks and other notable items
- The FDA had accepted the ONS-5010 BLA for filing with a review goal date of August 29, 2023. The EMA had validated the MAA; a decision was expected in 2024. These were expectations stated in the filing, not reported outcomes.
- Management said June cash plus $2.7 million net proceeds from July 2023 ATM share sales was expected to fund operations through the anticipated FDA decision in the third calendar quarter of 2023 and potentially through the fourth quarter. The company said substantial additional financing would be needed.
- The filing states there is substantial doubt about the company’s ability to continue as a going concern: available resources were not expected to fund at least 12 months of planned operations. Management was considering ATM sales, equity or debt financing, licensing, partnerships, and other funding; success was not assured.
- The December 2022 note has potentially dilutive conversion terms and restrictive provisions. Cash payments, including repayment, carry an additional 7.5% fee; specified defaults can increase the balance and permit acceleration, with default interest of 22% annually.
- Principal risks include regulatory approval and trial outcomes, manufacturing and vendor dependence, commercialization and market acceptance, financing availability and dilution, competition, and macroeconomic and banking-market disruption. Failure to secure funds could require curtailing programs or operations.
- The company terminated its prior Wainwright ATM agreement in May 2023 and entered a new BTIG ATM agreement permitting up to $100 million of share sales. July sales generated $2.7 million net proceeds. No material pending legal proceedings were reported; management concluded disclosure controls were effective.
Most important facts for investors to verify
- FDA action on the ONS-5010 BLA and any resulting approval conditions, timing, or additional requirements.
- Cash burn, cash runway, and the company’s ability to raise capital before resources are depleted.
- Terms, maturity, accrued balance, conversion mechanics, and repayment or default exposure under the December 2022 note.
- Actual ATM issuance, net proceeds, dilution, and remaining capacity under the BTIG agreement.
- Whether pre-launch spending and planned commercialization can be supported by available financing and whether the EMA review remains on track.